인슐린 펜 시장 규모, 점유율, 예측 및 동향 : 유형별, 당뇨병 유형별, 유통별, 헬스케어 환경별 - 세계 예측(-2031년)

Insulin Pens Market Size, Share, Forecast, & Trends Analysis by Type (Disposable, Reusable, Smart [Bluetooth, NFC]) Diabetes Type (Type 1, Type 2) Distribution (Hospital, Retail Pharmacies, E-commerce) Healthcare Setting-Global Forecast to 2031

The global insulin pens market is projected to reach over $6.73 billion by 2031 at a CAGR of 6.7% from 2024 to 2031.

Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of the increasing prevalence of diabetes, technological advancements in insulin pens, rising demand for self-administration of drugs, and rising diabetes awareness programs. However, the high cost of insulin pens, the availability of alternatives to insulin pens, and needle anxiety in patients restrain the growth of this market.

Furthermore, the rising preference for insulin pens over vials and syringes, emerging economies, and partnerships and collaborations by insulin manufacturing companies are expected to generate growth opportunities for the players operating in this market. However, lack of awareness and knowledge in developing countries and limited access to healthcare in developing countries are major challenges impacting market growth.

The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over four years (2021-2024). The key players operating in the global insulin pens market are Novo Nordisk A/S (Denmark), Eli Lilly and Company (U.S.), Sanofi S.A. (France), Biocon Limited (India), Becton, Dickinson and Company (U.S.), Ypsomed AG (Switzerland), Owen Mumford Limited (U.K.), Medtronic plc (Ireland), Emperra GmbH E-Health Technologies (Germany), pendiq GmbH (Germany), and Jiangsu Delfu medical device Co., Ltd (China).

Among all the types studied in this report, the disposable insulin pens segment is projected to register the highest CAGR of over 7.0% during the forecast period of 2024-2031. The high growth of this segment is attributed to the benefits offered by disposable insulin pens, such as their ability to cause less pain during administration. They come with a prefilled insulin cartridge loaded into the pen, and the entire product can be discarded after the cartridge is finished, minimizing the chances of infections.

Among all the applications studied in this report, in 2024, the type 1 diabetes segment is expected to account for the largest share of the insulin pens market. The large market share can be attributed to the increasing number of insulin-dependent patients and the rising number of type 1 diabetes cases. For instance, according to the International Diabetes Federation (IDF) data, in 2022, 8.75 million lived with type 1 diabetes globally. Out of which 1.52 million of these people were under 20 years old. Thus, the increasing number of type 1 diabetes cases drives the growth of this segment.

Among all the distribution channels studied in this report, in 2024, the distribution channel segment is expected to account for the largest share of the insulin pens market. Retail pharmacies often stock a diverse selection of insulin pens of different types. The increasing consumer demand for insulin pens and the opportunity for customers to inspect the product before making a purchase are the factors driving the growth of this segment.

Among all the healthcare settings studied in this report, in 2024, the home care segment is expected to account for the largest share of over 51.2% of the insulin pens market. The large market share of this segment can be attributed to the increasing development and adoption of home care devices due to their convenience, precision, and accuracy. Additionally, there has been a growing focus among companies to raise awareness about diabetes, which has led to increased adoption of insulin pens in home care settings.

An in-depth analysis of the geographical scenario of the global insulin pens market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2024, North America is expected to account for the largest share of over 37.8% of the insulin pens market. In the region in 2024, the U.S. is expected to account for the largest share of the insulin pens market in North America. The large share of the country is attributed to the presence of major insulin pen companies such as Eli Lilly and Company (U.S.) and Becton, Dickinson and Company (U.S.), increasing healthcare expenditure, rising demand for self-administration of drugs, and rising number of diabetes cases in this region are some of the major factors driving the growth of the region.

Scope of the Report:

Insulin Pens Market Assessment-by Type

• Disposable Insulin Pens
• Reusable Insulin Pens
• Smart Insulin Pens
  • Bluetooth Connectivity
  • Near Field Communication (NFC) Connectivity

Insulin Pens Market Assessment-by Application

• Type 1 Diabetes
• Type 2 Diabetes

Insulin Pens Market Assessment-by Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online/E-commerce Platforms

Insulin Pens Market Assessment-by Healthcare Setting

• Home Care
• Hospitals & Clinics
• Long-term Care Settings

Insulin Pens Market Assessment-by Geography

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • U.K
  • Italy
  • Spain
  • Austria
  • Netherlands
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa

TABLE OF CONTENTS

1. Introduction

• 1.1. Market Definition & Scope
• 1.2. Market Ecosystem
• 1.3. Currency & Limitations
• 1.4. Key Stakeholders

2. Research Methodology

• 2.1. Research Approach
• 2.2. Process of Data Collection & Validation
  • 2.2.1. Secondary Research
  • 2.2.2. Primary Research/Interviews with Key Opinion Leaders from the Industry
• 2.3. Market Sizing and Forecasting
  • 2.3.1. Market Size Estimation Approach
  • 2.3.2. Growth Forecast Approach
  • 2.3.3. Market Share Analysis
• 2.4. Assumptions for the Study

3. Executive Summary

4. Factors Affecting Market Growth

• 4.1. Overview
• 4.2. Drivers
  • 4.2.1. Increasing Prevalence of Diabetes
  • 4.2.2. Technological Advancements in Insulin Pens
  • 4.2.3. Rising Demand for Self-Administration of Drugs
  • 4.2.4 Rising Diabetes Awareness Programs
• 4.3. Restraints
  • 4.3.1. High Cost of Insulin Pens
  • 4.3.2. Availability of Alternatives to Insulin Pens
  • 4.3.3. Needle Anxiety in Patients
• 4.4. Opportunities
  • 4.4.1. Rising Preference for Insulin Pens over Vials and Syringes
  • 4.4.2. Emerging Economies
  • 4.4.3. Partnerships and Collaborations
• 4.5. Challenges
  • 4.5.1. Lack of Awareness and Knowledge in Developing Countries
  • 4.5.2. Limited Access to Healthcare in Developing Countries
• 4.6. Trends
  • 4.6.1. Smart Insulin Pens
  • 4.6.2. Prefilled Insulin Pens
• 4.7. Factor Analysis
• 4.8. Regulatory Analysis
  • 4.8.1. U.S.
  • 4.8.2. Canada
  • 4.8.3. Europe
  • 4.8.4. China
  • 4.8.5. Japan
  • 4.8.6. India
  • 4.8.7. Latin America
  • 4.8.8. Middle East
• 4.9. Pricing Analysis
• 4.10. Parent/Adjacent Market Analysis
• 4.11. Porter's Five Forces Analysis

5. Insulin Pens Market Assessment-by Type

• 5.1. Overview
• 5.2. Disposable Insulin Pens
• 5.3. Reusable Insulin Pens
• 5.4. Smart Insulin Pens
  • 5.4.1. Bluetooth Connectivity
  • 5.4.2. Near Field Communication (NFC) Connectivity

6. Insulin Pens Market Assessment-by Application

• 6.1. Overview
• 6.2. Type 1 Diabetes
• 6.3. Type 2 Diabetes

7. Insulin Pens Market Assessment-by Distribution Channel

• 7.1. Overview
• 7.2. Hospital Pharmacies
• 7.3. Retail Pharmacies
• 7.4. Online/E-commerce Platforms

8. Insulin Pens Market Assessment-by Healthcare Setting

• 8.1. Overview
• 8.2. Home Care
• 8.3. Hospitals & Clinics
• 8.4. Long-Term Care Settings

9. Insulin Pens Market Assessment-by Geography

• 9.1. Overview
• 9.2. North America
  • 9.2.1. U.S.
  • 9.2.2. Canada
• 9.3. Europe
  • 9.3.1. Germany
  • 9.3.2. France
  • 9.3.3. U.K.
  • 9.3.4. Italy
  • 9.3.5. Spain
  • 9.3.6. Austria
  • 9.3.7. Netherlands
  • 9.3.8. Rest of Europe
• 9.4. Asia-Pacific
  • 9.4.1. Japan
  • 9.4.2. China
  • 9.4.3. India
  • 9.4.4. Australia
  • 9.4.5. South Korea
  • 9.4.6. Rest of Asia-Pacific
• 9.5. Latin America
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America
• 9.6. Middle East & Africa

10. Competition Analysis

• 10.1. Overview
• 10.2. Key Growth Strategies
• 10.3. Competitive Benchmarking
• 10.4. Competitive Dashboard
  • 10.4.1. Industry Leaders
  • 10.4.2. Market Differentiators
  • 10.4.3. Vanguards
  • 10.4.4. Emerging Companies
• 10.5. Market Share Analysis/Market Rankings of Key Players (2023)

11. Company Profiles (Business Overview, Financial Overview, Product Portfolio, and Strategic Developments)

• 11.1. Novo Nordisk A/S
• 11.2. Eli Lilly and Company
• 11.3. Sanofi S.A.
• 11.4. Biocon Limited
• 11.5. Becton, Dickinson and Company
• 11.6. Ypsomed AG
• 11.7. Owen Mumford Limited
• 11.8. Medtronic plc
• 11.9. Emperra GmbH E-Health Technologies
• 11.10. pendiq GmbH
• 11.11. Jiangsu Delfu medical device Co. Ltd

(Note: SWOT analysis of the top 5 companies will be provided.)

12. Appendix

• 12.1. Available Customization
• 12.2. Related Reports